Clinical trial · Interventional
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
Detection of Hepatocellular Carcinoma by Positron Emission Tomography With C-Acetate-11 and F-fluorodeoxyglucose-18
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment. PURPOSE: This clinical trial is studying how well carbon-11 acetate PET and fludeoxyglucose F 18 PET work in detecting cancer in patients with liver cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 11Carbon-Acetate-PET | Procedure | — | UNRESOLVED |
| 18F-Fluorodeoxyglucose-PET (FDG-PET) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- PET scan (FDG-PET & 11C-acetate-PET)
- description
- Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
- interventionNames
- Procedure: 18F-Fluorodeoxyglucose-PET (FDG-PET)
- Procedure: 11Carbon-Acetate-PET
Primary outcomes (1)
- measure
- Relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18
Secondary outcomes (2)
- measure
- Determine whether PET identifies additional sites of disease not detected by conventional imaging
- measure
- Obtain a preliminary estimate of the impact of PET on management of patients with HCC.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
INCLUSION: * Biopsy-proved HCC (stage I and II by conventional staging) or one or more of the following in a patient with clinically documented cirrhosis: * AFP \> 200 mg/dL; * A contrast-enhancing tumor mass (\>1 cm) by CT or MRI; or * A tumor mass confirmed by arteriography. * Patient must provide written informed consent and have completed conventional imaging and staging before initiation of PET imaging. EXCLUSION: * Pediatric patients under the age of 18 will be excluded from consideration from this study. * Patients with a known prior malignancy (with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years will be excluded from entry into the study. However, patients with a prior HCC thought to have a new primary or recurrent HCC are eligible. * Pregnant and breastfeeding patients. * Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL)
References
Publications (0)
Data not yet available